Analysis of Gynecologic Cancer Management at Sanglah Hospital during COVID- 19 Pandemic

I Gde Sastra Winata, Ngakan Ketut Darmawan, I Nyoman Gede Budiana and I Nyoman Bayu Mahendra
Additional contact information
I Gde Sastra Winata: Medical Faculty of Udayana University, Indonesia
Ngakan Ketut Darmawan: Medical Faculty of Udayana University, Indonesia
I Nyoman Gede Budiana: Medical Faculty of Udayana University, Indonesia
I Nyoman Bayu Mahendra: Medical Faculty of Udayana University, Indonesia

European Journal of Medical and Health Sciences, 2022, vol. 4, issue 2, 4-7

Abstract: The COVID-19 pandemic presents its own challenges in treating cancer, especially gynecological cancer. The condition of cancer patients who have been immunocompromised either because of their disease or side effects of the drugs given, has the potential to increase the risk of cancer patients to experience severe COVID-19 infection. The main management of cancer, which is based on three axes, namely surgery, chemotherapy, and radiotherapy, needs to be adapted to increase survival rates. rates in patients.

Keywords: COVID-19; chemotherapy; gynecological cancer; operative; radiotherapy (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/ejmed/article/view/41283 Abstract page (text/html)
https://eu-opensci.org/index.php/ejmed/article/download/41283/9439 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:ejmed0:v:4:y:2022:i:2:id:41283

DOI: 10.24018/ejmed.2022.4.2.1283

Access Statistics for this article

More articles in European Journal of Medical and Health Sciences from European Open Science
Bibliographic data for series maintained by Support ().